Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
What Makes Amedisys (AMED) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Encompass Health (EHC) Gain From Inpatient Rehab Business?
by Zacks Equity Research
Encompass Health (EHC) is resorting to business restructuring to focus on core growth areas, which should expand its returns.
Amedisys (AMED) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Amedisys (AMED) Down 5.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Banks on Home Health & Hospice Amid Cost Woe
by Zacks Equity Research
Amedisys (AMED) continues to benefit from the recent acquisitions of hospice care providers.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
3 Reasons Why Amedisys (AMED) Is a Great Growth Stock
by Zacks Equity Research
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.
Amedisys (AMED) Beats Q3 Earnings Estimates, Ups 2020 View
by Zacks Equity Research
An impressive Q3 performance by Amedisys' (AMED) Home health and hospice amid the pandemic-led business disruptions buoys optimism.
Amedisys (AMED) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 76.38% and 2.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity
by Zacks Equity Research
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity
Pick These 5 Stocks With Superb Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Meritage Homes (MTH), Vertex Pharmaceuticals (VRTX), CVS Health (CVS), Amedisys (AMED) and Insperity (NSP) are sound enough to meet financial obligations.
Amedisys (AMED) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Is Amedisys (AMED) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys & BrightStar Ink Agreement to Expand Personal Care
by Zacks Equity Research
Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.
Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.
Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.
Amedisys (AMED) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 69.62% and 4.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amedisys (AMED) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys Rides on Coronavirus-Led Business Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.
Why the Earnings Surprise Streak Could Continue for Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ADUS vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. AMED: Which Stock Is the Better Value Option?
Healthcare for Silver Years to Aid Encompass Health (EHC)
by Zacks Equity Research
Encompass Health's (EHC) inpatient rehabilitation and home hospice businesses are poised to grow on the back of aging population.
Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes
by Zacks Equity Research
Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.